Ultragenyx Pharmaceutical Inc (RARE)
45.11
+1.42
(+3.25%)
USD |
NASDAQ |
Apr 23, 16:00
45.13
+0.02
(+0.04%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Gross Profit Margin (Quarterly): 90.54% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.54% |
| September 30, 2023 | 88.79% |
| June 30, 2023 | 90.85% |
| March 31, 2023 | 87.80% |
| December 31, 2022 | 94.85% |
| September 30, 2022 | 90.48% |
| June 30, 2022 | 90.74% |
| March 31, 2022 | 92.37% |
| December 31, 2021 | 95.79% |
| September 30, 2021 | 94.89% |
| June 30, 2021 | 96.39% |
| March 31, 2021 | 94.78% |
| December 31, 2020 | 94.01% |
| Date | Value |
|---|---|
| September 30, 2020 | 97.12% |
| June 30, 2020 | 97.08% |
| March 31, 2020 | |
| December 31, 2019 | 85.65% |
| September 30, 2019 | 89.60% |
| June 30, 2019 | 96.83% |
| March 31, 2019 | 97.51% |
| December 31, 2018 | 96.88% |
| September 30, 2018 | 97.68% |
| June 30, 2018 | 98.90% |
| March 31, 2018 | 97.89% |
| December 31, 2017 | 99.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
85.65%
Minimum
Dec 2019
97.12%
Maximum
Sep 2020
92.70%
Average
93.19%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 98.61% |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 88.87% |
| FibroGen Inc | 80.08% |
| Rocket Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -300.6% |
| Return on Assets | -43.52% |
| Return on Invested Capital | -300.6% |
| Profit Margin (Quarterly) | -96.70% |
| Operating Margin (Quarterly) | -95.81% |
| Return on Net Operating Assets | -102.5% |